Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II

Xu,Jianrong; Han,Qinghua; Shi,Hongtao; Liu,Wenyuan; Chu,Tingting; Li,Hao

doi:10.3892/ijmm.2017.3038

Role of PKA in the process of neonatal cardiomyocyte hypertrophy induced by urotensin II

Authors:
- Jianrong Xu
- Qinghua Han
- Hongtao Shi
- Wenyuan Liu
- Tingting Chu
- Hao Li
View Affiliations

Affiliations: Department of Cardiology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Cardiology, Linfen People's Hospital, Linfen, Shanxi 041000, P.R. China
Published online on: June 22, 2017 https://doi.org/10.3892/ijmm.2017.3038
Pages: 499-504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The model of urotensin II (UII)-induced cardiomyocyte hypertrophy has been widely used in studies on hypertrophy. However, the molecular mechanisms responsible for UII-induced cardiomyocyte hypertrophy have not yet been fully elucidated. It has been demonstrated that cardiomyocyte hypertrophy induced by UII is associated with changes in the intracellular Ca2+ concentration. In the present study, we investigated whether the cAMP-dependent protein kinase A (PKA)‑mediated upregulation of the phosphorylation levels of phospholamban (PLN) at Ser16 contributes to UII-induced cardiomyocyte hypertrophy. After primary cultures of neonatal rat cardiomyocytes were exposed to UII for 48 h, cell size, protein/DNA contents and intracellular Ca2+ levels were detected. Western blot analysis was used to quantify the phosphorylated and total forms of PKA, PLN and the total amount of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA)2a. UII increased the cell size, the protein/DNA ratio and the intracellular Ca2+ levels, consistent with the characteristics of hypertrophic response. In addition, exposure to UII upregulated the phosphorylation levels of PKA, and the expression levels of its downstream proteins, PLN and SERCA2a. However, treatment with PKA inhibitor (KT-5720) reversed all these effects of UII. On the whole, our results suggest that UII induces cardiomyocyte hypertrophy through the PKA-mediated upregulation of PLN phosphorylation at Ser16, which provides a new experimental foundation for the prevention and/or treatment of cardiac hypertrophy.

View Figures

View References

1	Levy D, Garrison RJ, Savage DD, Kannel WB and Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1561–1566. 1990. View Article : Google Scholar : PubMed/NCBI
2	Tang S, Chen H, Cheng Y, Nasir MA, Kemper N and Bao E: The interactive association between heat shock factor 1 and heat shock proteins in primary myocardial cells subjected to heat stress. Int J Mol Med. 37:56–62. 2016.PubMed/NCBI
3	Wu C, Dong S and Li Y: Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload. Int J Mol Med. 35:893–900. 2015.PubMed/NCBI
4	Liu P, Yan S, Chen M, Chen A, Yao D, Xu X, Cai X, Wang L and Huang X: Effects of baicalin on collagen I and collagen III expression in pulmonary arteries of rats with hypoxic pulmonary hypertension. Int J Mol Med. 35:901–908. 2015.PubMed/NCBI
5	Chen P, Li F, Xu Z, Li Z and Yi XP: Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy. Int J Mol Med. 32:165–173. 2013.PubMed/NCBI
6	Heineke J and Molkentin JD: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 7:589–600. 2006. View Article : Google Scholar : PubMed/NCBI
7	Guo H, Liu B, Hou L, The E, Li G, Wang D, Jie Q, Che W and Wei Y: The role of mAKAPβ in the process of cardiomyocyte hypertrophy induced by angiotensin II. Int J Mol Med. 35:1159–1168. 2015.PubMed/NCBI
8	Hill JA and Olson EN: Cardiac plasticity. N Engl J Med. 358:1370–1380. 2008. View Article : Google Scholar : PubMed/NCBI
9	Chuang CT, Guh JY, Lu CY, Chen HC and Chuang LY: S100B is required for high glucose-induced pro-fibrotic gene expression and hypertrophy in mesangial cells. Int J Mol Med. 35:546–552. 2015.
10	Zhang Y, Si Y and Ma N: Meis1 promotes poly (rC)-binding protein 2 expression and inhibits angiotensin II-induced cardiomyocyte hypertrophy. IUBMB Life. 68:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhou HM, Zhong ML, Zhang YF, Cui WY, Long CL and Wang H: Natakalim improves post-infarction left ventricular remodeling by restoring the coordinated balance between endothelial function and cardiac hypertrophy. Int J Mol Med. 34:1209–1218. 2014.PubMed/NCBI
12	Gong H, Ma H, Liu M, Zhou B, Zhang G, Chen Z, Jiang G, Yan Y, Yang C, Kanda M, et al: Urotensin II inhibits the proliferation but not the differentiation of cardiac side population cells. Peptides. 32:1035–1041. 2011. View Article : Google Scholar : PubMed/NCBI
13	Douglas SA, Tayara L, Ohlstein EH, Halawa N and Giaid A: Congestive heart failure and expression of myocardial urotensin II. Lancet. 359:1990–1997. 2002. View Article : Google Scholar : PubMed/NCBI
14	Liu JC, Chen CH, Chen JJ and Cheng TH: Urotensin II induces rat cardiomyocyte hypertrophy via the transient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor. Mol Pharmacol. 76:1186–1195. 2009. View Article : Google Scholar : PubMed/NCBI
15	Onan D, Pipolo L, Yang E, Hannan RD and Thomas WG: Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol. 18:2344–2354. 2004. View Article : Google Scholar : PubMed/NCBI
16	Gruson D, Ginion A, Decroly N, Lause P, Vanoverschelde JL, Ketelslegers JM, Bertrand L and Thissen JP: Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. Peptides. 31:1326–1333. 2010. View Article : Google Scholar : PubMed/NCBI
17	Maguire JJ and Davenport AP: Is urotensin-II the new endothelin? Br J Pharmacol. 137:579–588. 2002. View Article : Google Scholar : PubMed/NCBI
18	Domínguez-Rodríguez A, Díaz I, Rodríguez-Moyano M, Calderón-Sánchez E, Rosado JA, Ordóñez A and Smani T: Urotensin-II signaling mechanism in rat coronary artery: role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. Arterioscler Thromb Vasc Biol. 32:1325–1332. 2012. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Ying J, Jiang D, Chang Z, Li H, Zhang G, Gong S, Jiang X and Tao J: Urotensin-II receptor stimulation of cardiac L-type Ca²⁺ channels requires the βγ subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C β1 isoform. J Biol Chem. 290:8644–8655. 2015. View Article : Google Scholar : PubMed/NCBI
20	Rababa'h A, Singh S, Suryavanshi SV, Altarabsheh SE, Deo SV and McConnell BK: Compartmentalization role of A-kinase anchoring proteins (AKAPs) in mediating protein kinase A (PKA) signaling and cardiomyocyte hypertrophy. Int J Mol Sci. 16:218–229. 2014. View Article : Google Scholar : PubMed/NCBI
21	Masterson LR, Yu T, Shi L, Wang Y, Gustavsson M, Mueller MM and Veglia G: cAMP-dependent protein kinase A selects the excited state of the membrane substrate phospholamban. J Mol Biol. 412:155–164. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yin Z, Wang X, Zhang L, Zhou H, Wei L and Dong X: Aspirin attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting the Ca(2+)/Calcineurin-NFAT signaling pathway. Cardiovasc Ther. 34:21–29. 2016. View Article : Google Scholar
23	Fabiato A: Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 245:C1–C14. 1983.PubMed/NCBI
24	Bers DM: Cardiac excitation-contraction coupling. Nature. 415:198–205. 2002. View Article : Google Scholar : PubMed/NCBI
25	Bers DM: Ca transport during contraction and relaxation in mammalian ventricular muscle. Basic Res Cardiol. 92(Suppl 1): 1–10. 1997. View Article : Google Scholar : PubMed/NCBI
26	MacLennan DH and Kranias EG: Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 4:566–577. 2003. View Article : Google Scholar : PubMed/NCBI
27	Zhang C, Shan XL, Liao YL, Zhao P, Guo W, Wei HC and Lu R: Effects of stachydrine on norepinephrine-induced neonatal rat cardiac myocytes hypertrophy and intracellular calcium transients. BMC Complement Altern Med. 14:4742014. View Article : Google Scholar : PubMed/NCBI
28	Giordano A, Romano S, Mallardo M, D'Angelillo A, Calì G, Corcione N, Ferraro P and Romano MF: FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res. 79:519–526. 2008. View Article : Google Scholar : PubMed/NCBI
29	Maclennan DH: Interactions of the calcium ATPase with phospholamban and sarcolipin: structure, physiology and pathophysiology. J Muscle Res Cell Motil. 25:600–601. 2004.
30	Irie T, Sips PY, Kai S, Kida K, Ikeda K, Hirai S, Moazzami K, Jiramongkolchai P, Bloch DB, Doulias PT, et al: S-nitrosylation of calcium-handling proteins in cardiac adrenergic signaling and hypertrophy. Circ Res. 117:793–803. 2015. View Article : Google Scholar : PubMed/NCBI
31	Walsh DA and Van Patten SM: Multiple pathway signal transduction by the cAMP-dependent protein kinase. FASEB J. 8:1227–1236. 1994.PubMed/NCBI
32	Shioya T: A simple technique for isolating healthy heart cells from mouse models. J Physiol Sci. 57:327–335. 2007. View Article : Google Scholar : PubMed/NCBI
33	Yamazaki T, Komuro I, Zou Y, Kudoh S, Mizuno T, Hiroi Y, Shiojima I, Takano H, Kinugawa K, Kohmoto O, et al: Protein kinase A and protein kinase C synergistically activate the Raf-1 kinase/mitogen-activated protein kinase cascade in neonatal rat cardiomyocytes. J Mol Cell Cardiol. 29:2491–2501. 1997. View Article : Google Scholar : PubMed/NCBI
34	Komuro I and Yazaki Y: Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 55:55–75. 1993. View Article : Google Scholar : PubMed/NCBI
35	Shi H, Han Q, Xu J, Liu W, Chu T and Zhao L: Urotensin II induction of neonatal cardiomyocyte hypertrophy involves the CaMKII/PLN/SERCA 2a signaling pathway. Gene. 583:8–14. 2016. View Article : Google Scholar : PubMed/NCBI
36	Tölle M and van der Giet M: Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides. 29:743–763. 2008. View Article : Google Scholar
37	Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH and Willette RN: Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol. 131:1262–1274. 2000. View Article : Google Scholar : PubMed/NCBI
38	Bai XY, Liu XC, Yang Q, Tang XD and He GW: The interaction between human urotensin II and vasodilator agents in human internal mammary artery with possible clinical implications. Ann Thorac Surg. 92:610–616. 2011. View Article : Google Scholar : PubMed/NCBI
39	Shyu KG, Wang BW, Chen WJ, Kuan P and Lin CM: Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast. Eur J Clin Invest. 42:17–26. 2012. View Article : Google Scholar
40	Hassan GS, Chouiali F, Saito T, Hu F, Douglas SA, Ao Z, Willette RN, Ohlstein EH and Giaid A: Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol. 81:125–128. 2003. View Article : Google Scholar : PubMed/NCBI